Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS High Risk”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Testing effectiveness (Phase 2)UnknownNCT00885508
What this trial is testing

The Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 85
Large-scale testing (Phase 3)Ended earlyNCT04266301
What this trial is testing

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, Chronic
Novartis Pharmaceuticals 530
Not applicableUnknownNCT02905552
What this trial is testing

Myelodysplasic Syndromes and Risk Factors for Infection

Who this might be right for
Myelodysplastic Syndrome (MDS)InfectionRisk Factors+1 more
Assistance Publique - Hôpitaux de Paris 320
Not applicableStudy completedNCT05218902
What this trial is testing

Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Myeloid, Acute
Bristol-Myers Squibb 290
Testing effectiveness (Phase 2)Study completedNCT02197676
What this trial is testing

A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response

Who this might be right for
MDS
Groupe Francophone des Myelodysplasies 56
Testing effectiveness (Phase 2)Ended earlyNCT03946670
What this trial is testing

MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 127
Testing effectiveness (Phase 2)Study completedNCT00411905
What this trial is testing

Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 45
Testing effectiveness (Phase 2)Ended earlyNCT04812548
What this trial is testing

Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 20
Testing effectiveness (Phase 2)Study completedNCT01873703
What this trial is testing

Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndrome
Helsinn Healthcare SA 102
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT03151304
What this trial is testing

A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Helsinn Healthcare SA 64
Not applicableNot Yet RecruitingNCT07194187
What this trial is testing

High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction

Who this might be right for
Bladder Outlet ObstructionBPH
Icahn School of Medicine at Mount Sinai 17
Testing effectiveness (Phase 2)Ended earlyNCT00867308
What this trial is testing

Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia

Who this might be right for
Myelodysplastic Syndrome
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 32
Testing effectiveness (Phase 2)Ended earlyNCT01813838
What this trial is testing

GFM-Acadesine: A Phase I-II Trial of Acadesine

Who this might be right for
SMD
Groupe Francophone des Myelodysplasies 5
Testing effectiveness (Phase 2)WithdrawnNCT01324960
What this trial is testing

Azacitidine With or Without Ceplene/Interleukin-2 in Patients With Higher Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies
Testing effectiveness (Phase 2)Active Not RecruitingNCT04806906
What this trial is testing

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients

Who this might be right for
MDSCMML
University of Florence 11
Testing effectiveness (Phase 2)Study completedNCT03047993
What this trial is testing

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid Leukemia With Multilineage DysplasiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsBlasts 20-30 Percent of Peripheral Blood White Cells+4 more
M.D. Anderson Cancer Center 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT02944955
What this trial is testing

BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic Syndrome (MDS)
BioLite, Inc. 52
Testing effectiveness (Phase 2)UnknownNCT03380806
What this trial is testing

Prostate Boost Irradiation With Stereotactic Body RT (SBRT)

Who this might be right for
Prostate Cancer
Juravinski Cancer Center 100
Testing effectiveness (Phase 2)Ended earlyNCT04878432
What this trial is testing

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 39
Load More Results